Novel Compounds Targeting InhA for TB Therapy by Almatar, Manaf et al.
Novel compounds targeting InhA for TB therapy 
1Manaf AlMatar*, 2Essam A. Makky, 3IşılVar, 4Begüm Kayar,4Fatih Köksal 
1Department of Biotechnology, Institute of Natural and Applied Sciences (Fen 
BilimleriEnstitüsü) Cukurova University, Adana, Turkey 
2Department of Biotechnology, Faculty of Industrial Sciences and Technology, Universiti 
Malaysia Pahang (UMP), Kuantan, Malaysia 
3Department of Food Engineering, Agricultural Faculty, Cukurova University, Adana, Turkey 
4Department of Medical Microbiology, Faculty of Medicine, Çukurova University, Adana, 
Turkey 
*Address for correspondence:
E-mail: manafmatar19@gmail.com 
matarmanaf@gmail.com 
Mobile: +905355854644 
Graphical Abstract 
Abstract  
Tuberculosis (TB) is described as lethal disease in the world. Resistant to TB drugs is the main 
reason to have unfavourable outcomes in the treatment of TB. Therefore, new agents to replace 
existing drugs are urgently needed. Previous reports suggested that InhA inhibitors, an enoyl-ACP-
reductase, might provide auspicious candidates which can be developed into novel antitubercular 
agents.  In this review, we explain the role of InhA in the resistance of isoniazid. Furthermore, five 
classes of InhA inhibitors, which display novel binding modes and deliver evidence of their 
prosperous target engagement, have been debated.  
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1. Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), still remains the foremost 
cause of morbidity and mortality which accounts for nearly 9 million infections and 1.5 million 
deaths [1, 2]. Short course chemotherapy (SCC), which is considered the back-bone of anti-
tubercular chemotherapy, includes not only initial phase for two months but also continuation 
phase of treatment for four months. The initial phase of anti-tuberculosis treatment consists of 
isoniazid (INH) rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB), followed by INH 
and RIF for the continuation phase of four months [3, 4].  However, based on the guidelines of TB 
treatment, relapses and failures could be reduced by replacement of a regimen including RIF 
throughout the 2 month period with a regimen based on just 6 months of RIF [5].  
Although the most of TB instances are treatable, however, the current complex and long regimen 
of TB agents can lead to poor adherence with adverse side effects, therefore giving suboptimal 
therapy responses [4]. Even though many endeavours have been carried out to make the duration 
of treatment of drug-susceptible TB more shorter and to enhance the outcomes for MDR-TB 
therapies, the mortality rates are still high [6]. Thus, development of new antitubercular agents, 
which comprise novel chemical scaffolds with distinctive inhibitory binding modes and new 
modes of action, are urgently needed [7].  
The poorly permeable and very complex cell envelope of mycobacteria are considered as a main 
barrier in the conveyance of TB agents to their action site. The essential and major components of 
the mycobacterial cell envelope are a-branched, b-hydroxylated fatty acids with chains of carbon 
atoms between 60 and 90 in length. Two elongation systems comprise fatty acid synthase type I 
(FAS-I) and fatty acid synthase type II (FAS-II) control the mycobacterial cell envelope synthesis. 
FAS-I enzyme is only used by eukaryotic cells to synthesize fatty acids, thus the FAS-II enzymes 
are viable targets for drug development. InhA,  which is an enoyl-acyl carrier protein (ACP) 
